E-LIB Suche - Ergebnisse für: Dal-Ré, Rafael

1

Revisión por pares: consideraciones a las propuestas de Can..:

Dal-Ré, Rafael
Anales de Pediatría. 100 (2024) 4 - p. 311-312 , 2024

Link: https://doi.org/10.1016/..

2

Voluntary transparency of sponsors of medicines clinical tr..:

Dal-Ré, Rafael
Journal of Clinical Epidemiology. 169 (2024) - p. 111282 , 2024

Link: https://doi.org/10.1016/..

3

Revisión por pares: consideraciones a las propuestas de Can..:

Dal-Ré, Rafael
Anales de Pediatría. 100 (2024) 4 - p. 311-312 , 2024

Link: https://doi.org/10.1016/..

4

Is full transparency in clinical trials an achievable goal?:

Dal-Ré, Rafael
European Journal of Internal Medicine. 123 (2024) - p. 1-3 , 2024

Link: https://doi.org/10.1016/..

5

Principal Features of Industry-Funded Trials that Posted In..:

Dal-Ré, Rafael ; Mahillo-Fernández, Ignacio
The AAPS Journal. 26 (2024) 4 - p. , 2024

Link: https://doi.org/10.1208/..

6

Voluntary transparency of sponsors of medicines clinical tr..:

Dal-Ré, Rafael
Journal of Clinical Epidemiology. 169 (2024) - p. 111282 , 2024

Link: https://doi.org/10.1016/..

7

Adequate information about clinical trial results must be g..:

Dal-Ré, Rafael ; Caplan, Arthur L. ; Holm, Søren..
Nature Medicine. , 2024

Link: https://doi.org/10.1038/..

8

Challenges in conducting efficacy trials for new COVID-19 v..:

Dal-Ré, Rafael ; Bottieau, Emmanuel ; Launay, Odile..
Clinical Trials. , 2024

Link: https://doi.org/10.1177/..

9

'Time out'—more transparency is required in 'Just-in-time' ..:

Dal-Ré, Rafael ; Caplan, Arthur L ; Voo, Teck Chuan
European Journal of Internal Medicine. 108 (2023) - p. 100-101 , 2023

Link: https://doi.org/10.1016/..

10

Waivers of informed consent in research with competent part..:

Dal-Ré, Rafael
European Journal of Clinical Pharmacology. 79 (2023) 4 - p. 575-578 , 2023

Link: https://doi.org/10.1007/..

11

The Carlos III Research Institute and registration of clini..:

Dal-Ré, Rafael
Medicina Clínica (English Edition). 160 (2023) 2 - p. 94-95 , 2023

Link: https://doi.org/10.1016/..

12

Using the phases of clinical development of medicines to de..:

Dal-Ré, Rafael ; Banzi, Rita ; Cristea, Ioana A....
Journal of Clinical Epidemiology. 161 (2023) - p. 157-163 , 2023

Link: https://doi.org/10.1016/..

13

'Time out'—more transparency is required in 'Just-in-time' ..:

Dal-Ré, Rafael ; Caplan, Arthur L ; Voo, Teck Chuan
European Journal of Internal Medicine. 108 (2023) - p. 100-101 , 2023

Link: https://doi.org/10.1016/..

14

Regulatory agencies disregard real-world effectiveness evid..:

Dal-Ré, Rafael ; Porcher, Raphaël ; Rosendaal, Frits R..
Journal of Clinical Epidemiology. 153 (2023) - p. 83-90 , 2023

Link: https://doi.org/10.1016/..

15

Is it reasonable to label a trial as pragmatic whose invest..:

Dal-Ré, Rafael
Clinical Trials. 20 (2023) 3 - p. 319-321 , 2023

Link: https://doi.org/10.1177/..